Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study
Parita Shah, Yusuke Iwata, Eric E. Brown, et al.
European Archives of Psychiatry and Clinical Neuroscience (2019) Vol. 270, Iss. 1, pp. 11-22
Closed Access | Times Cited: 43

Showing 1-25 of 43 citing articles:

Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment
Masataka Wada, Yoshihiro Noda, Yusuke Iwata, et al.
Molecular Psychiatry (2022) Vol. 27, Iss. 7, pp. 2950-2967
Closed Access | Times Cited: 75
Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia
Antonio F. Pardiñas, Sophie Smart, Isabella R. Willcocks, et al.
JAMA Psychiatry (2022) Vol. 79, Iss. 3, pp. 260-260
Open Access | Times Cited: 68
Predictors of Treatment-Resistant and Clozapine-Resistant Schizophrenia: A 12-Year Follow-up Study of First-Episode Schizophrenia-Spectrum Disorders
Sherry Kit Wa Chan, Hei Yan Veronica Chan, William G. Honer, et al.
Schizophrenia Bulletin (2020) Vol. 47, Iss. 2, pp. 485-494
Open Access | Times Cited: 67
Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia
Mishal Qubad, Robert A. Bittner
Therapeutic Advances in Psychopharmacology (2023) Vol. 13
Open Access | Times Cited: 17
Demographic and clinical variables associated with response to clozapine in schizophrenia: a systematic review and meta-analysis
Kira Griffiths, Edward Millgate, Alice Egerton, et al.
Psychological Medicine (2021) Vol. 51, Iss. 3, pp. 376-386
Open Access | Times Cited: 31
Pharmacogenomics of Clozapine-induced agranulocytosis: a systematic review and meta-analysis
Farhana Islam, Daniel Hain, David Lewis, et al.
The Pharmacogenomics Journal (2022) Vol. 22, Iss. 4, pp. 230-240
Open Access | Times Cited: 19
Clozapine treatment and astrocyte activity in treatment resistant schizophrenia: A proton magnetic resonance spectroscopy study
Edgardo Torres‐Carmona, Ali Abdolizadeh, Yusuke Iwata, et al.
Schizophrenia Research (2024) Vol. 270, pp. 152-161
Closed Access | Times Cited: 4
Gamma‐aminobutyric acid (GABA) levels in the midcingulate cortex and clozapine response in patients with treatment‐resistant schizophrenia: A proton magnetic resonance spectroscopy (1H‐MRS) study
Fumihiko Ueno, Shinichiro Nakajima, Yusuke Iwata, et al.
Psychiatry and Clinical Neurosciences (2022) Vol. 76, Iss. 11, pp. 587-594
Closed Access | Times Cited: 18
The ever-growing case for clozapine in the treatment of schizophrenia: an obligation for psychiatrists and psychiatry
Robert A. Bittner, Andreas Reif, Mishal Qubad
Current Opinion in Psychiatry (2023) Vol. 36, Iss. 4, pp. 327-336
Open Access | Times Cited: 9
Predictors of response to pharmacological treatments in treatment-resistant schizophrenia – A systematic review and meta-analysis
A. Seppälä, Jenni Pylvänäinen, Heli Lehtiniemi, et al.
Schizophrenia Research (2021) Vol. 236, pp. 123-134
Open Access | Times Cited: 19
Long-Term Outcome of Clozapine in Treatment-Resistant Schizophrenia
Myung A. Lee, Philip A. Cola, Karu Jayathilake, et al.
Journal of Clinical Psychopharmacology (2023) Vol. 43, Iss. 3, pp. 211-219
Closed Access | Times Cited: 7
A predictor model of treatment resistance in schizophrenia using data from electronic health records
Giouliana Kadra-Scalzo, Daniela Fonseca de Freitas, Deborah Agbedjro, et al.
PLoS ONE (2022) Vol. 17, Iss. 9, pp. e0274864-e0274864
Open Access | Times Cited: 12
Decreased cortical gyrification and surface area in the left medial parietal cortex in patients with treatment‐resistant and ultratreatment‐resistant schizophrenia
Kazutoshi Kitajima, Shunsuke Tamura, Daiki Sasabayashi, et al.
Psychiatry and Clinical Neurosciences (2022) Vol. 77, Iss. 1, pp. 2-11
Open Access | Times Cited: 11
Quantitative biomarkers to predict response to clozapine treatment using resting EEG data
Kirill Masychev, C. Ciprian, Maryam Ravan, et al.
Schizophrenia Research (2020) Vol. 223, pp. 289-296
Closed Access | Times Cited: 15
Longitudinal course of cognition in schizophrenia: Does treatment resistance play a role?
Marco Spangaro, Francesca Martini, Margherita Bechi, et al.
Journal of Psychiatric Research (2021) Vol. 141, pp. 346-352
Closed Access | Times Cited: 13
Using a statistical learning approach to identify sociodemographic and clinical predictors of response to clozapine
Daniela Fonseca de Freitas, Giouliana Kadra-Scalzo, Deborah Agbedjro, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 4, pp. 498-506
Open Access | Times Cited: 8
Identification of novel functional brain proteins for treatment-resistant schizophrenia: Based on a proteome-wide association study
Wenming Wei, Huijie Zhang, Bolun Cheng, et al.
European Psychiatry (2023) Vol. 66, Iss. 1
Open Access | Times Cited: 4
Aberrant connectivity in the hippocampus, bilateral insula and temporal poles precedes treatment resistance in first-episode psychosis: a prospective resting-state functional magnetic resonance imaging study with connectivity concordance mapping
Stavros Skouras, Maria-Lisa Kleinert, Edwin Lee, et al.
Brain Communications (2024) Vol. 6, Iss. 3
Open Access | Times Cited: 1
Clozapine delay results in poorer outcomes for treatment resistant schizophrenia patients
Kalyani Rajalingham
Psiquiatría Biológica (2024) Vol. 31, Iss. 4, pp. 100493-100493
Closed Access | Times Cited: 1
Predicting treatment resistance in positive and negative symptom domains from first episode psychosis: Development of a clinical prediction model
Rebecca Lee, Siân Lowri Griffiths, Georgios V. Gkoutos, et al.
Schizophrenia Research (2024) Vol. 274, pp. 66-77
Closed Access | Times Cited: 1
An international clozapine titration guideline to increase its safety and move forward on the route started by German-speaking psychiatrists in the 1960s
José de León, Georgios Schoretsanitis, Can‐Jun Ruan, et al.
European Archives of Psychiatry and Clinical Neuroscience (2022) Vol. 272, Iss. 4, pp. 537-540
Open Access | Times Cited: 7
Relationship between plasma clozapine/N-desmethylclozapine and changes in basal forebrain-dorsolateral prefrontal cortex coupling in treatment-resistant schizophrenia
Deepak K. Sarpal, Annie Blazer, James Wilson, et al.
Schizophrenia Research (2022) Vol. 243, pp. 170-177
Open Access | Times Cited: 7
Feasibility and Effect of Increasing Clozapine Plasma Levels in Long-Stay Patients With Treatment-Resistant Schizophrenia
Jan Bogers, Peter F.J. Schulte, Theo G. Broekman, et al.
Journal of Clinical Psychopharmacology (2023) Vol. 43, Iss. 2, pp. 97-105
Closed Access | Times Cited: 3
The importance of early and proactive use of long-acting injectable antipsychotics in the management of schizophrenia
Hiroyoshi Takeuchi
International Clinical Psychopharmacology (2023) Vol. 38, Iss. 3, pp. 182-183
Closed Access | Times Cited: 2
Dopamine supersensitivity psychosis and delay of clozapine treatment in patients with treatment-resistant schizophrenia
Yuto Masumo, Nobuhisa Kanahara, Masanobu Kogure, et al.
International Clinical Psychopharmacology (2022)
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top